itary involvement, focused on the diagnosis [3] . Our patient is atypical in two points in addition to the point of overlapping Langerhans cell infiltration pathologically. First, he was found to have deficiencies of anterior pituitary hormones, as reported previously, accompanied with pituitary swelling. While it is known that ECD often involves central nervous system, there are only a handful of reports in which hypopituitarism due to ECD is investigated endocrinologically in detail. Secondly, his polyuria and polydipsia improved and he became not to need DDAVP three months after the treatment with interferon α. It is known that CDI does not tend to ameliorate even if primary disease such as inflammation [4] , infiltration [5, 6] or tumor [7, 8] , is successfully treated.
Apart from the previous report [3] , we focus on his endocrine clinical course and images before and after starting treatment with interferon α and zoledronic acid, accompanied with a review of the literature.
a Case report
A man in his early thirties was admitted to our hospital because of deteriorated fever, fatigue and joint pain. Based on imaging studies, histological findings and his clinical features, he was diagnosed with ECD [3] . Simultaneous endocrine examinations for polyuria, polydipsia, gynecomastia and loss of axillary hair and libido, revealed partial hypopituitarism with extremely low gonadotropins, sex hormones, and vasopressin, as reported previously. In detail, his cortisol level in the early morning was within normal range with elevated level of adrenocorticotropic hormone (ACTH). His prolactin (PRL), thyroid stimulating hormone (TSH), and free thyroxine (free T4) levels were within normal range, but free triiodothyronine (free T3), follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone, growth hormone (GH), and insulin like growth factor 1 (IGF-1) levels were decreased (Table 1) .
Pituitary MRI showed thickening of the pituitary stalk, enlargement of the anterior lobe with delayed enhancement and loss of high intensity of the posterior lobe in T1-weighted images ( Fig. 1-A1 , A2, A3). A hormonal provocative test revealed that the serum cortisol response to CRH was low in this patient although 
Fig. 1 Sequential pituitary MRIs
Before starting interferon α and zoledronic acid treatment, MRI showed thickening of the pituitary stalk, enlargement of the pituitary gland, and loss of high intensity of the posterior lobe on T1-weighted image (A1, A2, A3). Five months after starting the treatment, the thickening of the pituitary stalk was found to be reduced with slight recovery of high intensity of the posterior lobe in T1-weighted image (B1, B2, B3). One year after starting the treatment, enlargement of the anterior gland was found to be slightly increased with further recovery of high intensity of the posterior lobe in T1-weighted image (C1, C2, C3). One year and six months after starting treatment, there were no particular interval changes except for obscured high intensity of the posterior lobe on T1-weighted image (D1, D2, D3). Arrows indicate slightly recovered high intensity of the posterior lobe on T1-weighted images (B1, C1).
the basal level of ACTH was found to be high, that the GH response to GRH was low, that the TSH and PRL response to TRH was normal, and that the LH and FSH response to GnRH was low (Table 2) . A rapid ACTH infusion test revealed that the serum cortisol response to synthetic ACTH was slightly low ( Table 3) . The results of a hypertonic saline loading test followed by pitressin infusion were compatible with the presence of CDI (Table 4) . For deficit hormones, he started to be replaced with 10mg hydrocortisone, 2.5 µg of 1-desamino-8-D-arginine vasopressin (DDAVP) just before sleep and 5,000 IU hCG three times per week. These replacement therapies improved his manifestations, including nocturia. For the primary disease showing the severe bone pain and inflammatory reaction with high fever besides pituitary involvement, interferon α [9] [10] [11] [12] , at a dose of 10 6 IU subcutaneously three times a week, and zoledronic acid 4 mg per one month were started [13] in addition to non-steroid anti-inflammatory drugs and opioids (Fig. 2) .
In terms of pituitary involvement, symptoms of polyuria and polydipsia were ameliorated without DDAVP three months after starting the therapies. Subsequent (TRACP-5b) as a bone resorption marker remains to be low for two years. For four years, he has not showed any evidence of new involvement at other organs besides bones and the pituitary.
discussion
Erdheim-Chester disease is a rare non-Langerhans form of histiocytosis, characterized by multi-systemic xanthogranulomatous infiltration. To date about 500 cases have been reported in the literature [14] . The disease commonly affects the skeleton, but can involve the central nervous system, orbits, retroperitoneum, skin, and viscera such as heart, lung, liver and kidney. We experienced a unique ECD patient who presented with deficiencies in anterior pituitary hormones (hypopituitarism) besides CDI, which is known to be as one of the most common manifestations in ECD.
Hypopituitarism in ECD
As for CDI, a review of the published literatures showed that CDI was documented in 53 of 110 patients with ECD [15] . It has been reported that approximately one-quarter of the patients of ECD developed CDI, caused by infiltration of the pituitary gland [2, 14] . In contrast, deficiencies in anterior pituitary hormones have been described in limited numbers of cases (Table 5) .
MRI showed decreased thickening of the pituitary stalk and slight recover of high intensity of the posterior lobe in T1-weighted image ( Fig. 1-B1 , B2, B3). A decreased abnormal uptake in technetium-99m bone scintigraphy also supports the effectiveness of his therapy ( Fig.  3-A, B) . In contrast, one year later after starting the therapies, he needed to start thyroid hormone replacement therapy for secondary hypothyroidism, free T3 2.4 pg/mL, free T4 0.52 ng/dL, TSH 3.12 μU/mL. MRI showed slight enlargement of the anterior lobe in spite of further recovery of high intensity of the posterior lobe in T1-weighted image ( Fig. 1-C1 , C2, C3). One year and six months later after starting the therapies, MRI images did not show any particular interval changes except for obscured high intensity of the posterior lobe on T1-weighted image ( Fig. 1-D1 , D2, D3). Because there has been no sign of improvement for other pituitary hormones, he continues to be replaced with hydrocortisone and subcutaneous injection of hCG in addition to L-thyroxine without relapse of CDI. GH replacement therapy has been suspended because ECD is regarded as a proliferative disease.
In terms of bone involvement, there has been no sign of flare-up since five months after the therapies (Fig.  3-C, D) . Although monthly zoledronic acid was discontinued for osteonecrosis of the jaw bone 18 months later, levels of tartrate-resistant acid phosphatase 5b Fig. 3 A bone scintigraphy showed abnormal symmetric accumulation of technetium-99m increased in femora and tibiae before treatment (A). Five months after starting interferon α and zoledronic acid treatment, abnormal uptake in the bones was found to be decreased (B). One year after (C) and one year and six months after (D) starting treatment, abnormal uptake in the bones was unchanged. [34] , intrasellar pituitary xanthogranulomatous infiltration in the resected specimen suggests that hypopituitarism might be caused by the direct damage of anterior pituitary. However, basal PRL level is not available in these cases.
Based on the discussion above, our case (case 16) is atypical. He showed normal level of basal PRL and normal response to intravenous TRH, suggesting that the hypothalamic-pituitary portal system was still working. The other results of loading tests, revealing low reactions of ACTH and cortisol to CRH, GH to GRH and LH and FSH to GnRH, are compatible with damage at the pituitary level. MRIs showing involvement of anterior lobe and clinical improvement of CDI with interferon therapy are also supporting that the disorder of the anterior pituitary gland was the main cause of anterior pituitary hormone deficiency in our patient.
In summary, most reported cases of hypopituitarism in ECD had suprasellar mass or elevated basal PRL levels, indicating that they had disorders of the pituitary stalk or hypothalamus. In contrast, there are few cases in which the disorder of anterior pituitary gland itself seems to be the main cause of anterior pituitary hormone deficiency in ECD. From this point of view, we think that our case is valuable to report as a rare case.
Hypothalamic-pituitary imaging in ECD
Apart from the view of functional status of hypothalamic-infundibulo-pituitary axis, there is a report investigating the brain images in ECD patients [35] . In this report, it has been reported that hypothalamic-pituitary axis was involved in 16 (47%) of 33 ECD patients, most frequently, 14 showed loss of T1-high intensity at posterior lobe and 6 showed thickened stalk. In contrast, it did not mention about the anterior lobe or intrasellar involvement besides the loss of T1-high intensity of the posterior lobe. Some among the 6 patients showing thickened stalk might have shown hypopituitarism although they had not been evaluated from the point of hormonal status. In contrast, cardiovascular and central nervous system involvements have been well investigated in the point of fatalness. In fact, it has been reported that cardiovascular involvement is a major cause of death [36] and that CNS involvement is the independent clinical predictor of poor survival [11] Hypopituitarism can result from diseases of pituitary gland, pituitary stalk, and hypothalamus. Disorder at the level of hypothalamus leads to decreased production and secretion of stimulatory hormones such as CRH, TRH, GRH and GnRH, and of inhibitory hormones such as dopamine. Disorder at the level of pituitary stalk leads to disturbance of delivery of those hormones through hypophyseal portal system. Both disorders may lead to decreased secretion of ACTH, GH, LH, FSH and TSH, and to increased secretion of PRL from anterior pituitary, suggesting that increased level of PRL is a hallmark of disorder at the level of hypothalamus or stalk.
In the reported ECD cases showing hypopituitarism, 3 of 16 cases were described as having panhypopituitarism (Table 5 ). Among the remaining 13 cases, 11 cases had hypogonadotropic hypogonadism, 6 cases had GH deficiency, 4 cases had ACTH deficiency, and 4 cases had secondary hypothyroidism. Most of 16 cases showed supraseller mass and/or elevated level of PRL, indicating that they had disorders at the level of pituitary stalk or hypothalamus (Table 5 ). In detail, case 3 [16] , 4 [17] , 5 [18] and 8 [19] showed increased level of PRL. Among them, case 3 showed increased responses of PRL to TRH, and case 4 and 8 showed adequate responses of gonadotropin to GnRH in spite of showing hypogonadotropic hypogonadism, supporting the presence of suprasellar dysfunction. Case 12 [20] , 13 [21] and 14 [22] as well as case 5 showed suprasellar mass in MRIs, suggesting that their hypopituitarism is due to suprasellar dysfunction. In fact, in case 9 [23] , autopsy proved that the anterior lobe was intact and the posterior lobe was completely replaced by xanthogranulomatous infiltrates.
In contrast, 4 cases (case 1 [24] , 2 [25] , 6 [26] and 12) showed anterior pituitary hormone deficiency with normal level of PRL. However, not to mention the image of case 12, the image of case 2 showing thickened stalk and partially empty sella supports suprasellar damage despite of normal level of PRL. Case 1 and 6 with normal level of PRL showed hypogonadotropic hypogonadism without abnormalities in CT or MRI. In the cases of hypopituitarism caused by pituitary mass [27, 28] or apoplexy [29, 30] , gonadotropin is known as one of the pituitary hormones that are impaired early. However, case 1 and 6 showed no abnormalities in the images, supporting the possibility that they might not have shown structural disorder due to xanthogranulomatous infiltration, but might have been reported that interferon α shows direct inhibitory effects on thyroid hormone synthesis, release, and metabolism [39] . In contrast, several cases of hypopituitarism with no abnormality or a small cyst in MRIs have been reported in patients with chronic hepatitis virus infection undergoing interferon α treatment [40] . In our case, however, his thyroid dysfunction, secondary hypothyroidism, was more likely caused by pituitary involvement of ECD rather than by interferon α treatment, considering of slightly progressive enlargement of the pituitary gland in MRI (Fig. 1-C1, C2, C3) , pre-existing deficiencies in other pituitary hormones, and no improvement in thyroid dysfunction in spite of dose reduction of interferon α.
To be summarized, he showed different responses to treatment with interferon α between anterior pituitary lobe and posterior one. What mechanism caused this discrepancy of treatment effects? A hint might be in the point that bone specimen showed overlapping Langerhans cell infiltration histologically although there was no evidence in pituitary specimen. If Langerhans cells dominantly infiltrate anterior lobe and non-Langerhans cells dominantly posterior lobe and pituitary stalk, his unique clinical course showing secondary hypothyroidism with enlargement of anterior lobe and improvement of CDI with decreased thickening of pituitary stalk after starting interferon α treatment is interpretable. That's because anterior pituitary dysfunction is found in up to 20% of patients with Langerhans cell histiocytosis (LCH) [41] , interferon α treatment is not considered as effective approach for LCH, and established DI in LCH is generally permanent [41, 42] , based on previous reports. The point that our patient is in early adulthood is also compatible with overlapping LCH [43] [44] [45] .
Other endocrine involvement in ECD
Besides hypothalamic-pituitary involvement, enlargement of adrenal glands has been reported in some case reports [17] and 7 of the 22 patients [46] . Infiltration of thyroid [47, 48] , pancreas [49, 50] and testis [48, 51] has been reported in rare cases. For our patient, no other involvement besides bone and infundibulo-pituitary is evident from the images of whole body CT and FDG-PET.
Zoledronic acid for ECD
Bisphosphonates have been used for bone lesions of ECD causing bone pain and microfracture by targetin ECD. It is possible that hypopituitarism besides CDI would be evident in more patients than it was reported (Table 5) . It is to be seen whether hypopituitarism in ECD is really rare or not.
Treatment and outcome of hypopituitarism and CDI in ECD
For ECD, no standard treatment has been available and no case of cure has been reported so far. It has been reported that ECD patients were treated with glucocorticoids and/or cytotoxic agents in addition to radiation and operation [14, 37] , but the efficacy is still to debate. Interferon α has been used since the report of success in the treatment of ECD [9] . However, the efficacy seems to vary depending on patients and the sites of disease involvement, and it may not be effective for central nervous system and cardiovascular involvement [10] . However, recent multicenter analysis of 53 patients showed treatment with interferon α is as an independent predictor of survival [11] .
In terms of the function of posterior lobe, there have been few reports of improvement in CDI with therapy, although improvement of pituitary involvement in the images has been reported in some cases [10, 12] . For example, although 2 of 7 cases with the pituitary involvement improved in the images with long-term high dose interferon α [12] , they were not referred to hormonal improvement. Braiteh and colleagues [9] firstly reported that 2 of 3 ECD patients treated with interferon α showed gradual improvement in CDI. Since then, however, there is no other report referring to outcome of CDI in ECD with the treatment of interferon α. Our current patient improved in symptoms of CDI without DDAVP, accompanied with decreased thickening of pituitary stalk after treatment for several months. Considering CDI, especially in children and young adults, is caused by destruction or degeneration of the neurons that originate in the supraoptic and paraventricular nuclei of the hypothalamus [38] and does not tend to ameliorate even if primary disease such as inflammation, infiltration or tumor is successfully treated, our case is unique.
In terms of the function of anterior lobe, there have been very few reports. Interestingly, our patient developed secondary hypothyroidism while sign and symptom of CDI disappeared without DDAVP. Interferon α often causes thyroid dysfunction due to autoimmune thyroid disease such as destructive thyroiditis, chronic thyroiditis and Graves' disease. Furthermore it has but also the foamy macrophages when skeletal manifestations flare up again.
In summary, we report a patient of ECD with pituitary involvement, focusing on endocrine clinical course and images before and after treatment, especially CDI and anterior pituitary hormone deficiencies with MRIs. He showed different responses to treatment with interferon α between anterior pituitary lobe and posterior one. We thus think it is important to assess and follow endocrine status in addition to imaging studies in ECD patients with pituitary involvement.
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appendix
WBC, white blood cell; Seg, segmented cell; Eosino, eosinophile; LYM, lymphocyte; Hb, hemoglobin; Hct, hematocrit; PLT, platelet; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; T-Bil, total bilirubin; BUN, blood urea nitrogen; Cre, creatinine; Na, sodium; K, potassium; Cl, chloride; UA, uric acid; CPK, creatine phosphokinase; CRP, C-reactive protein; s-OSM, serum osmolarity; u-OSM, urine osmolarity; u-Na, urine sodium; u-Cre, urine creatinine; FPG, fasting plasma glucose; HbA1c (JDS), hemoglobin A1c (Japan Diabetes Society) ing for osteoclasts [13, [52] [53] [54] [55] [56] [57] . In fact, it was reported that ECD patients treated with zoledronic acid, pamidronate, or alendronate showed significant relief of bone pain [13, 55, 57] and biochemical marker of bone turnover [54] , homologous to patients with bone metastatic lesions of malignant tumor [58] . As for our patient, treatment with interferon α and monthly zoledronic acid relieved bone pain with decreased level of CRP. Although zoledronic acid was discontinued for osteonecrosis of the jaw bone 18 months later, his bone pain has been controlled with low level of TRACP-5b for the subsequent two years. It might be attributed to the effect of regularly administered interferon α, However, considering the reports showing that zoledronic acid can be found in bone, soft tissue, and plasma 8 months after injection and that a single infusion of zoledronic acid produces sustained effect beyond a year [59] , the prolonged effect of zoledronic acid in our patient may be attributed to its accumulation in the bone matrix.
Pro-inflammatory cytokines, such as interleukin-1α (IL-1α), tumor necrosis factor α (TNF-α) and IL-6, were reported to be strongly expressed in the foamy macrophages of ECD [31] . These cytokines released by the foamy macrophages can stimulate osteoclast activity, and bisphosphonate can play a role in inhibiting the activity. In addition to these cytokines, receptor activator of NF-kappaB ligand (RANKL) was reported to be expressed in the foamy macrophages of bone lesion (53%) and lung (15%) [31] . If this is the case, administration of anti-RANKL antibody might be a therapeutic option in our patient, by targeting not only to osteoclast references
